146.30

0.17% -0.3447

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$146.64

Offen:

$145.46

24-Stunden-Volumen:

171.19K

Relative Volume:

0.02

Marktkapitalisierung:

$181.43B

Einnahmen:

$29.79B

Nettoeinkommen (Verlust:

$9.22B

KGV:

19.91

EPS:

7.3494

Netto-Cashflow:

$10.23B

1W Leistung:

-2.15%

1M Leistung:

+9.89%

6M Leistung:

-0.16%

1J Leistung:

+26.46%

1-Tages-Spanne:

$145.00

$146.72

1-Wochen-Bereich:

$145.00

$151.48

52-Wochen-Spanne:

$108.46

$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Firmenname

Gilead Sciences Inc

Sektor

Healthcare (1087)

Branche

Drug Manufacturers - General (20)

Telefon

(650) 574-3000

Adresse

333 LAKESIDE DR, FOSTER CITY, CA

Mitarbeiter

17,000

Twitter

@GileadSciences

Nächster Verdiensttermin

2026-10-29

Neueste SEC-Einreichungen

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GILD Gilead Sciences Inc	146.32	181.83B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,131.79	1.00T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	268.51	648.55B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	248.82	439.62B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	148.47	366.28B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	138.50	261.73B	54.66B	13.58B	16.05B	7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-10	Eingeleitet	Jefferies	Buy
2026-02-20	Eingeleitet	Barclays	Equal Weight
2026-02-11	Bestätigt	Needham	Buy
2026-01-07	Fortgesetzt	UBS	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-08-19	Hochstufung	Daiwa Securities	Neutral → Outperform
2025-08-08	Hochstufung	Truist	Hold → Buy
2025-07-25	Hochstufung	Needham	Hold → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-03-04	Bestätigt	Oppenheimer	Outperform
2025-02-18	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-13	Hochstufung	DZ Bank	Hold → Buy
2025-01-10	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Fortgesetzt	BofA Securities	Buy
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Buy
2024-11-08	Herabstufung	Maxim Group	Buy → Hold
2024-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-17	Eingeleitet	Bernstein	Outperform
2024-10-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-07-08	Hochstufung	Raymond James	Mkt Perform → Outperform
2024-05-01	Bestätigt	Maxim Group	Buy
2024-04-24	Hochstufung	HSBC Securities	Reduce → Hold
2024-02-22	Herabstufung	Truist	Buy → Hold
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-09-08	Hochstufung	BofA Securities	Neutral → Buy
2023-09-06	Eingeleitet	HSBC Securities	Reduce
2023-07-24	Bestätigt	Barclays	Equal Weight
2023-05-16	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Fortgesetzt	Piper Sandler	Overweight
2023-01-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Fortgesetzt	BofA Securities	Neutral
2022-12-09	Herabstufung	DZ Bank	Buy → Hold
2022-10-31	Hochstufung	Barclays	Underweight → Equal Weight
2022-10-28	Bestätigt	BMO Capital Markets	Market Perform
2022-10-28	Bestätigt	Cowen	Outperform
2022-10-28	Bestätigt	JP Morgan	Overweight
2022-10-28	Bestätigt	Jefferies	Buy
2022-10-28	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-28	Bestätigt	RBC Capital Mkts	Outperform
2022-10-28	Hochstufung	Truist	Hold → Buy
2022-10-28	Bestätigt	Wells Fargo	Equal Weight
2022-10-04	Hochstufung	JP Morgan	Neutral → Overweight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-02-28	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Bestätigt	BMO Capital Markets	Outperform
2022-02-02	Bestätigt	BofA Securities	Neutral
2022-02-02	Bestätigt	RBC Capital Mkts	Outperform
2022-02-02	Bestätigt	Truist	Hold
2022-02-02	Bestätigt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Argus	Hold → Buy
2022-01-06	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Fortgesetzt	Wells Fargo	Equal Weight
2021-12-06	Eingeleitet	Goldman	Neutral
2021-11-19	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Fortgesetzt	Piper Sandler	Neutral
2021-10-20	Fortgesetzt	Cowen	Outperform
2021-07-30	Bestätigt	BMO Capital Markets	Market Perform
2021-07-30	Bestätigt	RBC Capital Mkts	Outperform
2021-04-01	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-03-30	Hochstufung	Redburn	Neutral → Buy
2021-01-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-11-03	Fortgesetzt	Morgan Stanley	Equal-Weight
2020-10-28	Eingeleitet	UBS	Neutral
2020-09-30	Fortgesetzt	Jefferies	Buy
2020-09-15	Hochstufung	Maxim Group	Hold → Buy
2020-07-31	Bestätigt	Credit Suisse	Neutral
2020-07-31	Bestätigt	Morgan Stanley	Equal-Weight
2020-07-31	Bestätigt	Piper Sandler	Overweight
2020-07-31	Bestätigt	RBC Capital Mkts	Outperform
2020-07-31	Bestätigt	SunTrust	Hold
2020-07-31	Bestätigt	Wells Fargo	Equal Weight
2020-07-20	Hochstufung	Credit Suisse	Underperform → Neutral
2020-06-03	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Hochstufung	SunTrust	Sell → Hold
2020-05-01	Herabstufung	JP Morgan	Overweight → Neutral
2020-05-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-05-01	Herabstufung	SunTrust	Hold → Sell
2020-04-27	Herabstufung	UBS	Buy → Neutral
2020-04-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Herabstufung	CFRA	Hold → Sell

Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

06:59 AM

Gilead launches research facility in US for new medicine development - Yahoo Finance

06:59 AM

06:01 AM

NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

06:01 AM

Sep 08, 2026

How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st

Sep 08, 2026

Gilead opens new building on existing Foster City campus - NBC Bay Area

Sep 08, 2026

Gilead National Ribbon Cutting Ceremony - Post Register

Sep 08, 2026

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Sep 08, 2026

Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa

Sep 08, 2026

Assembly Bio stock gains after exercising Gilead profit option - Investing.com India

Sep 08, 2026

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - marketwatch.com

Sep 08, 2026

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times

Sep 08, 2026

A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan

Sep 08, 2026

Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma

Sep 08, 2026

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - TradingKey

Sep 08, 2026

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences

Sep 08, 2026

Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS

Sep 08, 2026

Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Moomoo

Sep 08, 2026

Gilead opens research center as $32 billion US build-out continues - The Pharma Letter

Sep 08, 2026